Evidence map›Paper›PMID 37314509›Full record

ArticleEJNMMI research2023

From bench to bedside:

Silvano Gnesin, Nicolas Chouin, Michel Cherel, Steven Mark Dunn, Niklaus Schaefer, Alain Faivre-Chauvet, John O Prior, Judith Anna Delage

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJNMMI research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Preclinical evaluation of DOTAGA.Glu.(FAPI)European journal of nuclear medicine and molecular imaging · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Silvano GnesinInstitute of Radiation Physics, Lausanne University Hospital and University of Lausanne, 1011, Lausanne, Switzerland.ORCID http://orcid.org/0000-0002-6547-3824
Nicolas ChouinInserm, CNRS, University of Angers, Oniris, CRCI2NA, University of Nantes, Nantes, France.ORCID http://orcid.org/0000-0003-1489-4351
Michel CherelCHU Nantes, CNRS, Inserm, CRCINA, University of Nantes, 44000, Nantes, France.ORCID http://orcid.org/0000-0001-6347-6848
Steven Mark DunnLAbCore, Ludwig Institute for Cancer Research, Lausanne University Hospital and University of Lausanne, 1066, Epalinges, Switzerland.ORCID http://orcid.org/0000-0002-7402-9581
Niklaus SchaeferDepartment of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital and University of Lausanne, Rue du Bugnon 46, 1011, Lausanne, Switzerland.ORCID http://orcid.org/0000-0002-9732-7696
Alain Faivre-ChauvetCHU Nantes, CNRS, Inserm, CRCINA, University of Nantes, 44000, Nantes, France.ORCID http://orcid.org/0000-0003-3849-0087
John O PriorDepartment of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital and University of Lausanne, Rue du Bugnon 46, 1011, Lausanne, Switzerland. John.Prior@chuv.ch.ORCID http://orcid.org/0000-0003-1429-1374
Judith Anna DelageRadiopharmacy Unit, Department of Pharmacy, Lausanne University Hospital and University of Lausanne, 1011, Lausanne, Switzerland.ORCID http://orcid.org/0000-0003-3039-5173

Funding

Agence Nationale de la Recherche IGO LabEx n° ANR-11-LABX-0016-01Agence Nationale de la Recherche IRON LabEx n° ANR-11-LABX-0018-01Agence Nationale de la Recherche n° ANR-11-EQPX-0004Agence Nationale de la Recherche n° ANR-16-IDEX-0007
6 · The paper itself

Abstract

The development of diagnostic and therapeutic radiopharmaceuticals is an hot topic in nuclear medicine. Several radiolabeled antibodies are under development necessitating both biokinetic and dosimetry extrapolations for effective human translation. The validation of different animal-to-human dosimetry extrapolation methods still is an open issue. This study reports the mice-to-human dosimetry extrapolation of

Indexed as

Clinical translationCopper-64Dose extrapolationDosimetryFusion protein antibodyLutetium-177PET imagingRadioimmunotherapyTheranosticTumor endothelial marker 1

Identifiers

PMID37314509
PMCPMC10267050

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.